Steve Harr's Net Worth
$102 Million
Who is Steve Harr?
Steve Harr has an estimated net worth of $102 Million. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., Loxo Oncology, Inc., and Juno Therapeutics, Inc..
SEC CIK
Steve Harr's CIK is 0001627387
Past Insider Trading and Trends
2017 was Steve Harr's most active year for acquiring shares with 7 total transactions. Steve Harr's most active month to acquire stocks was the month of January. 2018 was Steve Harr's most active year for disposing of shares, totalling 12 transactions. Steve Harr's most active month to dispose stocks was the month of February. 2017 saw Steve Harr paying a total of $228,900.00 for 228,423 shares, this is the most they've acquired in one year. In 2018 Steve Harr cashed out on 1,270,602 shares for a total of $47,331,429.96, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Sana Biotechnology, Inc. (SANA) Snapshot price: $6.29
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 2
| |||
Form 4
| -4.09% | -334.00K |
—
|
—
| 7.84M |
Apr 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 3
| |||
Form 4
| +33.07% | 2.03M |
—
|
—
| 8.17M |
Feb 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Loxo Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Juno Therapeutics, Inc. No price found
CFO & Head, Corp. Development
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -639.52K |
$87.00 |
—
|
0
|
Mar 5
| |||
Form 4
| +1.84% | 11.54K |
—
|
—
| 639.52K |
Feb 27
| |||
Form 4
| -20.76% | -164.49K |
$85.49 | -$145,674.96 | 627.97K |
Feb 7
| |||
Form 4
| +3.82% | 29.14K |
—
|
—
| 792.47K |
Jan 31
| |||
Form 4
|
—
|
0
|
$26.74 | -$315,373.72 | 763.33K |
Scheduled
|
Dec 21
| ||
Form 4
| +4.93% | 35.89K |
—
|
—
| 763.33K |
Oct 20
| |||
Form 4
|
—
|
0
|
$19.36 | -$186,200.00 | 727.44K |
Scheduled
|
Jul 3
| ||
Form 4
|
—
|
0
|
$19.36 | -$186,200.87 | 727.44K |
Scheduled
|
Jun 27
| ||
Form 4
| +3.92% | 27.44K |
—
|
—
| 727.44K |
Feb 7
| |||
Form 4
| -4.11% | -30.00K |
$43.32 | -$1,299,529.65 | 700K |
Scheduled
|
Jun 10
| ||
Form 4
| -0.68% | -5.00K |
$45.00 | -$225,000.00 | 730K |
Scheduled
|
Mar 4
| ||
Form 4
| -3.92% | -30.00K |
$37.58 | -$1,127,341.65 | 735K |
Scheduled
|
Mar 1
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
| -4.38% | -35.00K |
$46.43 | -$1,625,074.16 | 765K |
Scheduled
|
Dec 10
| ||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Mar 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||